1 Min Read
Jan 4 (Reuters) - Bayer AG
* Regorafenib from Bayer granted priority review in USA For second-line treatment of liver cancer Source text for Eikon: Further company coverage: (Reporting By Georgina Prodhan)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.